SRSF2, RUNX1 and ASXL1 frequently occur in patients with newly diagnosed AML with one TP53 mutation, whereas KRAS/NRAS, PTPN11, and RUNX1 commonly occur in ≥2 TP53 mutations [56]. Here, TP53 is linked to acute myeloid leukemia.